JP5193859B2 - 抗菌剤としてのキノリン誘導体 - Google Patents

抗菌剤としてのキノリン誘導体 Download PDF

Info

Publication number
JP5193859B2
JP5193859B2 JP2008518812A JP2008518812A JP5193859B2 JP 5193859 B2 JP5193859 B2 JP 5193859B2 JP 2008518812 A JP2008518812 A JP 2008518812A JP 2008518812 A JP2008518812 A JP 2008518812A JP 5193859 B2 JP5193859 B2 JP 5193859B2
Authority
JP
Japan
Prior art keywords
alkyl
compound
alkyloxy
use according
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008518812A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008546825A5 (enExample
JP2008546825A (ja
Inventor
アンドリース，ケンラート・ジヨゼフ・ロデビーク・マルセル
コウル，アニル
ギルモン，ジエローム・エミール・ジヨルジユ
モツト，マガリ・マデレーヌ・シモーヌ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of JP2008546825A publication Critical patent/JP2008546825A/ja
Publication of JP2008546825A5 publication Critical patent/JP2008546825A5/ja
Application granted granted Critical
Publication of JP5193859B2 publication Critical patent/JP5193859B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2008518812A 2005-06-28 2006-06-26 抗菌剤としてのキノリン誘導体 Expired - Fee Related JP5193859B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05105769 2005-06-28
EP05105769.3 2005-06-28
PCT/EP2006/063556 WO2007000436A1 (en) 2005-06-28 2006-06-26 Quinoline derivatives as antibacterial agents

Publications (3)

Publication Number Publication Date
JP2008546825A JP2008546825A (ja) 2008-12-25
JP2008546825A5 JP2008546825A5 (enExample) 2009-08-20
JP5193859B2 true JP5193859B2 (ja) 2013-05-08

Family

ID=35445742

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008518812A Expired - Fee Related JP5193859B2 (ja) 2005-06-28 2006-06-26 抗菌剤としてのキノリン誘導体

Country Status (33)

Country Link
US (2) US20100204270A1 (enExample)
EP (1) EP1898910B1 (enExample)
JP (1) JP5193859B2 (enExample)
KR (1) KR101423229B1 (enExample)
CN (1) CN101252928B (enExample)
AP (1) AP2733A (enExample)
AR (1) AR057654A1 (enExample)
AU (1) AU2006263884B2 (enExample)
BR (1) BRPI0612534B8 (enExample)
CA (1) CA2612623C (enExample)
CY (1) CY1118515T1 (enExample)
DK (1) DK1898910T3 (enExample)
EA (1) EA014163B1 (enExample)
ES (1) ES2606772T3 (enExample)
HR (1) HRP20161704T1 (enExample)
HU (1) HUE031268T2 (enExample)
IL (1) IL188394A (enExample)
JO (1) JO3270B1 (enExample)
LT (1) LT1898910T (enExample)
ME (1) ME02690B (enExample)
MX (1) MX2008000082A (enExample)
MY (1) MY151030A (enExample)
NO (1) NO341283B1 (enExample)
NZ (1) NZ564339A (enExample)
PL (1) PL1898910T3 (enExample)
PT (1) PT1898910T (enExample)
RS (1) RS55408B1 (enExample)
SG (1) SG166799A1 (enExample)
SI (1) SI1898910T1 (enExample)
TW (1) TWI392494B (enExample)
UA (1) UA91549C2 (enExample)
WO (1) WO2007000436A1 (enExample)
ZA (1) ZA200711149B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9790186B2 (en) 2009-07-21 2017-10-17 Trustees Of Dartmouth College Composition and method for prevention, mitigation or treatment of an enteropathogenic bacterial infection
CN104254527B (zh) 2012-04-27 2017-05-31 詹森药业有限公司 抗菌的喹啉衍生物
AU2013254670B2 (en) 2012-04-27 2017-03-30 Janssen Pharmaceutica Nv Antibacterial quinoline derivatives
CN105037497B (zh) * 2015-03-27 2018-06-26 中牧实业股份有限公司 一种恩拉霉素的提纯方法
WO2017035288A1 (en) * 2015-08-27 2017-03-02 Trustees Of Dartmouth College Composition and method for prevention, mitigation or treatment of an enteropathogenic bacterial infection

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103905A (en) * 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
DE19937116A1 (de) * 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin Kochsalzformulierung
DK2301544T3 (da) * 2002-07-25 2013-01-02 Janssen Pharmaceutica Nv Quinolinderivater som mellemprodukter til mykobakterielle inhibitorer
EP1753427B1 (en) * 2004-05-28 2008-04-02 Janssen Pharmaceutica N.V. Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
EE05394B1 (et) * 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis

Also Published As

Publication number Publication date
ME02690B (me) 2017-10-20
EA200800152A1 (ru) 2008-06-30
CY1118515T1 (el) 2017-07-12
IL188394A (en) 2012-09-24
CA2612623A1 (en) 2007-01-04
JO3270B1 (ar) 2018-09-16
NZ564339A (en) 2011-02-25
AU2006263884A1 (en) 2007-01-04
ES2606772T3 (es) 2017-03-27
PT1898910T (pt) 2016-11-16
BRPI0612534A2 (pt) 2010-11-23
SI1898910T1 (sl) 2017-01-31
NO20080481L (no) 2008-02-29
AP2733A (en) 2013-09-30
KR101423229B1 (ko) 2014-07-25
RS55408B1 (sr) 2017-04-28
MY151030A (en) 2014-03-31
AR057654A1 (es) 2007-12-12
JP2008546825A (ja) 2008-12-25
AU2006263884B2 (en) 2013-01-10
TW200738237A (en) 2007-10-16
HUE031268T2 (en) 2017-06-28
IL188394A0 (en) 2008-08-07
CN101252928A (zh) 2008-08-27
BRPI0612534B8 (pt) 2021-05-25
EP1898910B1 (en) 2016-09-28
ZA200711149B (en) 2009-06-24
SG166799A1 (en) 2010-12-29
NO341283B1 (no) 2017-10-02
PL1898910T3 (pl) 2017-03-31
BRPI0612534B1 (pt) 2020-04-22
HRP20161704T1 (hr) 2017-02-10
DK1898910T3 (en) 2017-01-09
US20100204270A1 (en) 2010-08-12
LT1898910T (lt) 2017-01-10
MX2008000082A (es) 2008-03-24
BRPI0612534A8 (pt) 2017-12-26
HK1120734A1 (en) 2009-04-09
EA014163B1 (ru) 2010-10-29
UA91549C2 (ru) 2010-08-10
CA2612623C (en) 2016-09-27
EP1898910A1 (en) 2008-03-19
WO2007000436A1 (en) 2007-01-04
US20130030017A1 (en) 2013-01-31
KR20080028460A (ko) 2008-03-31
TWI392494B (zh) 2013-04-11
CN101252928B (zh) 2012-05-23

Similar Documents

Publication Publication Date Title
JP5410753B2 (ja) 抗バクテリア剤としてのキノリン誘導体
CN101232884B (zh) 作为抗菌剂的喹啉衍生物
JP5302680B2 (ja) 抗バクテリア剤としてのキノリン誘導体
US20130030017A1 (en) Quinoline derivatives as antibacterial agents
JP5193857B2 (ja) 抗菌剤としてのキノリン誘導体
JP5208739B2 (ja) 抗菌剤としてのキノリン誘導体
JP5193858B2 (ja) 抗菌剤としてのキノリン誘導体
JP5349730B2 (ja) 抗バクテリア剤としてのキノリン誘導体
HK1122210B (en) Quinoline derivatives as antibacterial agents
BG109179A (bg) Хинолинови производни като антибактериални средства
HK1120734B (en) Quinoline derivatives as antibacterial agents
HK1124232B (en) Quinoline derivatives as antibacterial agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090625

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090625

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120522

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120817

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120824

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120913

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120921

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121019

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121121

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130129

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130204

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 5193859

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160208

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees